Latest Articles

Publication Date
Organon Ends Development of OG-6219 After Endometriosis Trial Fails to Meet Primary Endpoint - MarketScreener

Organon Ends Development of OG-6219 After Endometriosis Trial Fails to Meet Primary Endpoint MarketScreener

Published: July 2, 2025, 12:10 p.m.
Organon halts development of endometriosis pain drug after trial failure By Investing.com - Investing.com Canada

Organon halts development of endometriosis pain drug after trial failure By Investing.com Investing.com Canada

Published: July 2, 2025, 12:08 p.m.
Organon to halt development of endometriosis pain drug after mid-stage trial failure - MarketScreener

Organon to halt development of endometriosis pain drug after mid-stage trial failure MarketScreener

Published: July 2, 2025, 11:52 a.m.
Organon abandons endometriosis pain drug development after trial failure - MarketScreener

Organon abandons endometriosis pain drug development after trial failure MarketScreener

Published: July 2, 2025, 11:52 a.m.
Organon halts development of endometriosis pain drug after trial failure - Investing.com

Organon halts development of endometriosis pain drug after trial failure Investing.com

Published: July 2, 2025, 11:42 a.m.
Endometriosis linked to four-times higher pregnancy rates than other causes of infertility, study reveals - Medical Xpress

Endometriosis linked to four-times higher pregnancy rates than other causes of infertility, study reveals Medical Xpress

Published: July 2, 2025, 11:33 a.m.
Organon's Promising Endometriosis Drug OG-6219 Falls Short in Critical Phase 2 Trial, Program Discontinued - Stock Titan

Organon's Promising Endometriosis Drug OG-6219 Falls Short in Critical Phase 2 Trial, Program Discontinued Stock Titan

Published: July 2, 2025, 11:30 a.m.
AstraZeneca Pharma India gains CDSCO approval for treating endometrial cancer in the country - Express Pharma

AstraZeneca Pharma India gains CDSCO approval for treating endometrial cancer in the country Express Pharma

Published: July 2, 2025, 7 a.m.
AstraZeneca Pharma India gets CDSCO nod for expanded use of Imfinzi in Endometrial Cancer - Medical Dialogues

AstraZeneca Pharma India gets CDSCO nod for expanded use of Imfinzi in Endometrial Cancer Medical Dialogues

Published: July 2, 2025, 6:31 a.m.
XBP1 promotes endometrial fibrosis through cGAS-STING signaling pathway in intrauterine adhesion - Nature

XBP1 promotes endometrial fibrosis through cGAS-STING signaling pathway in intrauterine adhesion Nature

Published: July 2, 2025, 5:48 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!